Despite the challenges in developing PRMT1‐targeted therapies, combination strategies employing PRMT1 inhibitors with PARP inhibitors (PARPis) or immunotherapeutic agents demonstrate considerable potential to overcome drug resistance and remodel the tumor microenvironment. This evidence concerns the gene PRMT1 and neoplasm.